Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The KABOOM was the sound of Dilution.
Yes sure gradual increases are best.
I have never sold a single share.
Been buying for a long long time.
I just think the regurgitation is getting real old and the dilution is absolutely ridiculous.
Its taking too long to do a deal with Lympro.
It sure does'nt take to long to sell shares in the company below market though does it.
I would prefer a transitional time now where we get the agreements sooner than later and stop the ruining of our share holdings.
Its easy for a CEO to reverse split and re-issue himself more shares, for the rest of us we are getting ripped off right now.
Yes, a Hail Marry Pass will do of our corporate goals.
Lets get the Ball moving.
MANF, Wolfram, and Diabetes #3: Protecting remaining tissues
I am getting many questions about MANF, and many people are looking at my blogs related to this topic.
http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html
http://wolframsyndrome.blogspot.com/2014/04/manf-wolfram-and-diabetes-part2.html
We became interested in MANF several years ago. Although we have not published any articles related to MANF, we have been accumulating data. The reason we are actively studying MANF is that this molecule may be able to protect remaining pancreatic beta cells and brain cells in patients with Wolfram syndrome and type 1 diabetes. I will tell you more about our strategy in my next blog.
http://wolframsyndrome.blogspot.com/2014/05/four-pillars-to-provide-cure-for.html
Posted by Fumihiko Urano at 6:41 AM
http://wolframsyndrome.blogspot.com/2014/06/manf-wolfram-and-diabetes-3-protecting.html
Just what exchange for up listing
A CEO that keeps increasing shares as the price moves up he reminds me of half of you on this board. Like JP
Posting share price every five minutes. Grow up team and hope this football player has more real plays ahead. We need a hail marry pass right now.
BC-SeraPro (The Breast Cancer Diagnostic Blood Test) may be the wildcard and may be potentially "immediately ready" for fast-track commercialization much sooner than LymPro will be. BC-SeraPro could come into play as a unexpected pleasant surprise to everyone!
Amarantus now owns the IP rights to BC-SeraPro after acquiring all the IP rights from Power3 Medical Products:
http://ir.stockpr.com/amarantus/company-news/detail/473/amarantus-bioscience-acquires-neurodegenerative-diagnostic-intellectual-property-portfolio-from-power3-medical-products
An old press release article by Power3 Medical Products concerning the commercialization of BC-SeraPro:
http://www.reuters.com/article/2008/01/08/idUS140999+08-Jan-2008+BW20080108
From the recent Amarantus 10-K:
For the next 12 months, the Company intends to focus on the development of MANF and the development of LymPro. The Company intends to use minimal resources and look for appropriate research partnership opportunity to further develop its BC-SeraPro, NuroPro and PhenoGuard assets.
Thanks for quick reply on another 90% blood test ownership by AMBS -BC SeraPro oncology diagnostic platform
With application in breast cancer.
Well it's 90% plus accurate for breast cancer
What's current status. Owned by AMBS
BC-SeraPro, an oncology diagnostic platform with application in breast cancer;
On the Yahoo Profile for AMBS a Blood test for Breast Cancer,
is listed.
http://finance.yahoo.com/q/pr?s=AMBS+Profile
When reviewing it, it shows a 90% success rate. Its circa 2008 and may have been acquired.
Anyone know about this?
It's listed in yahoo profile
This is a brand page for the BC-SERAPRO trademark by Power3 Medical Products, Inc. in The Woodlands, TX, 77381. Write a review about a product or service associated with this BC-SERAPRO trademark. Or, contact the owner Power3 Medical Products, Inc. of the BC-SERAPRO trademark by filing a request to communicate with the Legal Correspondent for licensing, use, and/or questions related to the BC-SERAPRO trademark.
Bc serapro cancer blood test
Does ambs own this
http://www.trademarkia.com/bcserapro-77165513.html
Nothing like a Roach Killer, AMBS
Amarantus BioScience Holdings, Inc., a development stage biotechnology company, focuses on the discovery and development of drug and diagnostic product candidates to treat human diseases in the United States. The company?s principal products in development include the lymphocyte proliferation test, a diagnostic blood test for Alzheimer?s disease; Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinson?s disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials; and Mesencephalic Astrocyte-derived Neurotrophic factor, a therapeutic protein for use in Parkinson?s disease and other apoptosis-related disorders treatment. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson?s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.
How to Apply for Designation as an Orphan Product
Subpart C
Designation of an Orphan Drug § 316.20 Content and format of a request for orphan drug designation.
(a) A sponsor that submits a request for orphan drug designation of a drug for a specified rare disease or condition shall submit each request in the form and containing the information required in paragraph (b) of this section. A sponsor may request orphan drug designation of a previously unapproved drug, or of a new orphan indication for an already marketed drug. In addition, a sponsor of a drug that is otherwise the same drug as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent drug for the same rare disease or condition if it can present a plausible hypothesis that its drug may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation of the same drug for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation as provided in paragraph (b) of this section.
(b) A sponsor shall submit two copies of a completed, dated, and signed request for designation that contains the following:
(1) A statement that the sponsor requests orphan drug designation for a rare disease or condition, which shall be identified with specificity.
(2) The name and address of the sponsor; the name of the sponsor's primary contact person and/or resident agent including title, address, and telephone number; the generic and trade name, if any, of the drug or drug product; and the name and address of the source of the drug if it is not manufactured by the sponsor.
(3) A description of the rare disease or condition for which the drug is being or will be investigated, the proposed indication or indications for use of the drug, and the reasons why such therapy is needed.
(4) A description of the drug and a discussion of the scientific rationale for the use of the drug for the rare disease or condition, including all data from nonclinical laboratory studies, clinical investigations, and other relevant data that are available to the sponsor, whether positive, negative, or inconclusive. Copies of pertinent unpublished and published papers are also required.
(5) Where the sponsor of a drug that is otherwise the same drug as an already approved orphan drug seeks orphan drug designation for the subsequent drug for the same rare disease or condition, an explanation of why the proposed variation may be clinically superior to the first drug.
(6) Where a drug is under development for only a subset of persons with a particular disease or condition, a demonstration that the subset is medically plausible.
(7) A summary of the regulatory status and marketing history of the drug in the United States and in foreign countries, e.g., IND and marketing application status and dispositions, what uses are under investigation and in what countries; for what indication is the drug approved in foreign countries; what adverse regulatory actions have been taken against the drug in any country.
(8) Documentation, with appended authoritative references, to demonstrate that:
(i) The disease or condition for which the drug is intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic drug, or preventive drug, the persons to whom the drug will be administered in the United States are fewer than 200,000 per year as specified in § 316.21(b), or
(ii) For a drug intended for diseases or conditions affecting 200,000 or more people, or for a vaccine, diagnostic drug, or preventive drug to be administered to 200,000 or more persons per year in the United States, there is no reasonable expectation that costs of research and development of the drug for the indication can be recovered by sales of the drug in the United States as specified in § 316.21(c). (9) A statement as to whether the sponsor submitting the request is the real party in interest of the development and the intended or actual production and sales of the product.
(c) Any of the information previously provided by the sponsor to FDA under Subpart B of this part may be referenced by specific page or location if it duplicates information required elsewhere in this section
Reference:
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm135122.htm
Are 700 human tests enough for PD in Orphan Status.
Orphan Status would propel this into single Digits.
The Market cap would get to a Billion real quick.
We are at about 77 million right now. For you non math types,
about a $1.30 Dollar Thirty cents. So not to worry about 10 cents.
ok. Are you really concerned about a penny?
A disease is defined as rare in the U.S. if it is believed to affect fewer than 200,000 Americans. Approximately 30 million Americans have rare diseases. NORD provides advocacy, education, research and patient services on behalf of those patients and their families.
Reinstating the Orphan Products Board established in the Orphan Drug Act of 1983 Establishing an Office of Clinical Trial Design within the NIH National Center for Advancing Translational Sciences (NCATS) Establishing an Office of Clinical Endpoints within NCATS Federal incentives to increase knowledge of rare diseases among physicians in training Establishing a Rare Disease Ombudsman within the Department of Health and Human Services (HHS) Ensuring access to orphan therapies by addressing prohibitive cost-sharing structures within both public and private health plans Reforming the Institutional Review Board (IRB) system for assessing new therapies Creating an “Orphan Protected Class” within the Medicare Part D Program Establishing clearer federal policies with regard to off-label use of drugs and the issuance of information about those uses
- See more at: http://blog.rarediseases.org/nord-outlines-steps-to-promote-innovative-drug-discovery-development-and-delivery-for-americans-with-rare-diseases/#sthash.EkxKinIr.dpuf
http://blog.rarediseases.org/nord-outlines-steps-to-promote-innovative-drug-discovery-development-and-delivery-for-americans-with-rare-diseases/
" I always carry a card articulating my strategy to provide a cure for Wolfram syndrome. I think there are four pillars to provide a cure for Wolfram syndrome.
1. Stop the progression of the disease.
We are looking for FDA-approved drugs that can delay the progression of Wolfram syndrome. These drugs are currently used for other indications. We are also developing new drugs specifically designed for Wolfram.
2. Raise Awareness
It is important to raise awareness of Wolfram in health care professionals and the general public. We need a list of doctors who have experience in managing patients with Wolfram.
3. Replace damaged tissues
We are creating eye cells, brain cells, and pancreatic beta cells from patients' skin cells (iPS technology). We are also correcting genetic mutations in these cells (genome editing technology).
4. Protect remaining tissues
We are looking for a trophic factor that can protect remaining brain cells and beta cells from dysfunction and death. MANF and MANF-related molecule that we have identified are good candidates.
" end quote
http://wolframsyndrome.blogspot.com/2014/05/four-pillars-to-provide-cure-for.html
http://1.bp.blogspot.com/-IywzjPatvPU/U4oEBQokeKI/AAAAAAAAAN4/8TdpPOxldXs/s1600/IMG_3830.jpg
AMBS moving
Shareholders sleeping for AMBS SAN FRAN TIME
L.D. Micro Conference - June 4,2014 - Los Angeles
Luxe Hotel
11461 Sunset Boulevard
Los Angeles, CA 90049
http://www.ldmicro.com/
I think we will be hearing from Dr. Urano soon.
Dr, Urano Blog update .. mentions MANF as Candidate for Drug Target
MANF - Needed to preserve cells - Diabetes / Wolfram treatment
He carries around the post card to remind himself of the focus.
URANO - MANF Drawing
http://1.bp.blogspot.com/-IywzjPatvPU/U4oEBQokeKI/AAAAAAAAAN4/8TdpPOxldXs/s1600/IMG_3830.jpg
Solantey, its .09 cents, who cares.
I don't care if you have the worlds largest storage of
of rats to feed the MANF needs for tests.
YOur a net seller of the stock when it rallies.
true flipper
Reference: Washington Univ St. Louis Univ
http://www.icts.wustl.edu/icts-researchers/about/highlight-your-discoveries/urano-wolfram
Please understand these are long term studies above.
Quick money, possible, but be prepared to hold long term.
MANF, Wolfram, and Diabetes: What is MANF? Why did the biotech license my invention?
Since a biotech company in California licensed my invention on Quote: "MANF for therapeutics and diagnostics for Wolfram syndrome and Type 1 diabetes, I have been getting a lot of emails on this topic. I would like to briefly explain you about MANF. In short, MANF is one of our targets for developing patient-based therapeutics and diagnostics for Wolfram syndrome and type 1 diabetes.
MANF stands for mesencephalic astrocyte-derived neurotrophic factor. This molecule is created in our body, and it was originally isolated from a type of brain cells called astrocytes. Several years ago, we discovered that MANF was secreted from pancreatic beta cells and neurons when their endoplasmic reticulum calcium was depleted. We thought that this was a potential biomarker for Wolfram syndrome and filed an invention disclosure. Interestingly, we found several articles reporting that MANF can confer protection against neuronal cell death mediated by endoplasmic reticulum dysfunction. So we started testing if MANF might confer protection against pancreatic beta cell death mediated by ER dysfunction, and the preliminary results were positive."
Reference:
http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html
WOW - MANF this is amazing, Wolframs image Urano,
MANF is implicated as saving the cells from death
http://wolframsyndrome.blogspot.com/
Regarding Concussions and White House Initiatives
Posted Since AMBS is directly contributing to this cause.
The NCAA and the Department of Defense are jointly launching a $30 million effort to fund the most comprehensive clinical study of concussion and head impact exposure ever conducted and to issue an Educational Grand Challenge aimed at improving concussion safety behaviors in college sports and the military. This initiative aims to produce research on concussion risks, treatment and management through a multi-site longitudinal clinical study and advanced research projects. Through an Educational Grand Challenge, the initiative aims to create novel and impactful evidence-based concussion education materials and solicit research proposals to identify key factors for affecting change in the culture and behavior of college student-athlete and other young adult populations with regard to concussions.
Reference:
http://politics.suntimes.com/article/washington/obama-guidance-press-schedule-may-29-2014-sports-concussions/thu-05292014-901am
How old is Wolframs indication in terms of discovery?
One Billionaire, family and friends that is. oh well I blew my cover.
AMBS is the one to buy before its too late!
Told some friends with some big cash about it.
They are long term types.
MANF Mitigates phosphorylation in Alzheimer's
So does deficiency of CD40 2006.
When is shareholders meeting
It's only a slice of a penny yes Gerald needs to present agreements not back peddling where is the up list information?
I for one have not seen a CEO SO slow to complete a task vs hinting around like a school boy. We need the agreement vs the conjecture.
Our current efforts May 28, 2014
I would like to briefly outline our current efforts.
1. Develop drugs that can delay the progression of Wolfram syndrome.
As of today, we are focusing on one FDA-approved drug. We are testing the efficacy of this drug in iPS cells from patients and two animal models of Wolfram syndrome. We are also testing two new types of drugs.
2. Making eye cells using iPS cells derived from Wolfram syndrome patients.
As of today, we started seeing eye-like cells in our dishes. I am excited by this. We will keep on differentiating these cells and test the efficacy of our candidate drugs to develop treatments for eye manifestations in Wolfram syndrome.
3. Measuring the levels of disease-progression biomarkers
We have identified two potential disease-progression biomarkers. As of today, we are measuring the levels of these markers in blood samples from patients and control subjects.
4. Correcting genetic mutations using CRISPR technology in cells from Wolfram syndrome patients.
In the future, we need to correct genetic mutations in pancreatic beta cells, brain cells, and eye cells derived from patients' skin cells before they are transplanted. We are performing a "molecular surgery" to replace a mutated segment of WFS1 gene with a normal segment of WFS1 gene in cells from patients.
http://wolframsyndrome.blogspot.com/2014_05_01_archive.html
Lympro and MANF will drive this well over $1.00
http://ir.stockpr.com/amarantus/company-news/detail/1024/amarantus-licenses-manf-related-wolframs-and-diabetes-therapeutic-and-diagnostic-intellectual-property-from-university-of-massachusetts-medical-school
With 20,000,000 20million available at any price? Are you guys kidding me, this stock and its technology is worth 1billion right now.
- AMBS GOING TO .75 CENTS - near term
its only %1000 approx from here
happens all the time.
Start Believing and seeing this in your Mind. Believe.
Dws, he believes he's broke, so he stays in the gutter.
The rest of you are believers, I believe its going
10x higher, and that's the entry point for the rest of the
investment world. It could go up 50,000%.